Literature DB >> 30938444

How to integrate immunotherapy into standard of care in glioblastoma.

Michael Platten1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30938444      PMCID: PMC6556846          DOI: 10.1093/neuonc/noz043

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  Actively personalized vaccination trial for newly diagnosed glioblastoma.

Authors:  Norbert Hilf; Sabrina Kuttruff-Coqui; Katrin Frenzel; Valesca Bukur; Stefan Stevanović; Cécile Gouttefangeas; Michael Platten; Ghazaleh Tabatabai; Valerie Dutoit; Sjoerd H van der Burg; Per Thor Straten; Francisco Martínez-Ricarte; Berta Ponsati; Hideho Okada; Ulrik Lassen; Arie Admon; Christian H Ottensmeier; Alexander Ulges; Sebastian Kreiter; Andreas von Deimling; Marco Skardelly; Denis Migliorini; Judith R Kroep; Manja Idorn; Jordi Rodon; Jordi Piró; Hans S Poulsen; Bracha Shraibman; Katy McCann; Regina Mendrzyk; Martin Löwer; Monika Stieglbauer; Cedrik M Britten; David Capper; Marij J P Welters; Juan Sahuquillo; Katharina Kiesel; Evelyna Derhovanessian; Elisa Rusch; Lukas Bunse; Colette Song; Sandra Heesch; Claudia Wagner; Alexandra Kemmer-Brück; Jörg Ludwig; John C Castle; Oliver Schoor; Arbel D Tadmor; Edward Green; Jens Fritsche; Miriam Meyer; Nina Pawlowski; Sonja Dorner; Franziska Hoffgaard; Bernhard Rössler; Dominik Maurer; Toni Weinschenk; Carsten Reinhardt; Christoph Huber; Hans-Georg Rammensee; Harpreet Singh-Jasuja; Ugur Sahin; Pierre-Yves Dietrich; Wolfgang Wick
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

2.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors:  Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

3.  Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.

Authors:  Junseong Park; Chang Gon Kim; Jin-Kyoung Shim; Jong Hoon Kim; Hoyoung Lee; Jae Eun Lee; Min Hwan Kim; Keeok Haam; Inkyung Jung; Su-Hyung Park; Jong Hee Chang; Eui-Cheol Shin; Seok-Gu Kang
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

4.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Authors:  John H Sampson; Kenneth D Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

5.  Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

Authors:  Smita S Chandran; Robert P T Somerville; James C Yang; Richard M Sherry; Christopher A Klebanoff; Stephanie L Goff; John R Wunderlich; David N Danforth; Daniel Zlott; Biman C Paria; Arvind C Sabesan; Abhishek K Srivastava; Liqiang Xi; Trinh H Pham; Mark Raffeld; Donald E White; Mary Ann Toomey; Steven A Rosenberg; Udai S Kammula
Journal:  Lancet Oncol       Date:  2017-04-07       Impact factor: 41.316

6.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

7.  Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.

Authors:  Aida Karachi; Changlin Yang; Farhad Dastmalchi; Elias J Sayour; Jianping Huang; Hassan Azari; Yu Long; Catherine Flores; Duane A Mitchell; Maryam Rahman
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

Review 8.  Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.

Authors:  Mirco Friedrich; Lukas Bunse; Wolfgang Wick; Michael Platten
Journal:  Curr Opin Oncol       Date:  2018-11       Impact factor: 3.645

9.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

10.  Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Authors:  Tiffany R Hodges; Martina Ott; Joanne Xiu; Zoran Gatalica; Jeff Swensen; Shouhao Zhou; Jason T Huse; John de Groot; Shulin Li; Willem W Overwijk; David Spetzler; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

View more
  3 in total

1.  Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.

Authors:  Dipongkor Saha; Samuel D Rabkin; Robert L Martuza
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 2.  Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Authors:  Kevin Dzobo; Dimakatso Alice Senthebane; Chelene Ganz; Nicholas Ekow Thomford; Ambroise Wonkam; Collet Dandara
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

3.  High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency.

Authors:  Jan R H Hanauer; Vivian Koch; Ulrich M Lauer; Michael D Mühlebach
Journal:  Mol Ther Oncolytics       Date:  2019-10-23       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.